Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

WALTHAM, Mass., Dec. 9 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today top-line results from a Phase 3 clinical trial to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with a history of pancreatitis. The study's co-primary endpoints were improvements in sensitivity of detection of structural abnormalities of the pancreatic ducts using RG1068 in combination with MRI compared to MRI alone with minimal loss in specificity (<7.5%). The study design used endoscopy as the standard for determination of structural abnormalities. The predetermined criteria for a successful study were achievement of a statistically significant improvement in sensitivity with minimal loss in specificity from two of the three central radiologists reading the MRI images. In this study, one radiologist achieved a statistically significant improvement in sensitivity with RG1068 (p<0.001) while a second radiologist showed a trend but did not achieve statistical significance (p=0.088). There was minimal loss in specificity for all radiologists. While it was not a pre-specified endpoint, pooled data from all three radiologists resulted in a statistically significant improvement in sensitivity with RG1068 (p=0.005) with minimal loss in specificity.

The RG1068-enhanced MRI images showed highly statistically significant improvements on other endpoints for all radiologists including improvements in image quality (p<0.001), ability to see all three segments of the pancreatic duct (p<0.001), and physician confidence in their ability to identify pancreatic duct abnormalities (p<0.001), when compared to MRI alone. There were no serious adverse events (SAEs) associated with the RG1068-MRI procedures compared to 55 SAEs associated
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The clinical and ... be the difference between a product,s success or failure. ... and stratify KOL targets – and then to coordinate ... of strong relationships upon which successful KOL engagement rests. ... companies have identified internal inconsistencies in their KOL management ...
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
(Date:8/29/2014)... Healthpointe Medical Group, one of ... center from LAXMed. The medical center is less than 2 ... west of the 405 freeway. , The LAX clinic ... LAX center is located at: 8610 S. Sepulveda Blvd., Suite ... Healthpointe LAX office will provide the same comprehensive services ...
(Date:8/29/2014)... The family of a California woman ... dialysis treatments has filed a GranuFlo lawsuit ( http://www.thegranuflolawsuit.com ... of Fresenius Medical Care’s GranuFlo and NaturaLyte dialysis concentrates, ... file d in Alameda County Superior Court on July ... resulted in metabolic alkalosis, a dangerous elevation of ...
(Date:8/29/2014)... 29, 2014 Today, NBC’s “The ... who profiled a handful of safe, back to ... Research. This year, many schools will include earphones ... innovator of hearing wellness solutions, offers the best ... Earphones, offered in yellow, pink and black, sound ...
(Date:8/29/2014)... Reinberg HealthDay Reporter ... majority of American babies are getting the vaccines they ... officials said Thursday. More than 90 percent of ... and rubella (MMR); polio; hepatitis B and chickenpox (varicella), ... Prevention. "Nationally, vaccination among children 19 to 35 ...
(Date:8/29/2014)... Food and Drug Administration (FDA)-approved treatment for decreasing ... effective at reducing fracture risk as other current ... loss. With the use of wide- and small-angle ... out experiments at the U.S. Department of Energy,s ... Laboratory that revealed an additional mechanism underlying raloxifene ...
Breaking Medicine News(10 mins):Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Revealing a novel mode of action for an osteoporosis drug 2
... with a drug that targets two genes that ... this deadly disease, according to cancer researchers. The ... safer and more effective way of targeting cancer-causing ... , "It is a very selective and ...
... message boards, videos and advice , , MONDAY, Sept. 15 ... cancer patients learn more about how they can preserve ... Northwestern University in Chicago. , "It,s overwhelming for ... fertility preservation at the same time that they are ...
... Sept. 15 Yearbook photos capture school,portraits for years ... a,yearbook photo that they would prefer to erase -- ... yearbook photos this year, and to,kick-off the launch of ... & CLEAR(R) is inviting teens to,"Erase Their Worst Year ...
... Consumer coalition calls for quality standards to protect Pennsylvania ... families from inadequate regulations, ... allow facilities to rent rooms to residents that,do not meet ... wheelchairs or walkers., While new assisted living construction would ...
... LSU Health Sciences Center New Orleans School of ... the Robert Wood Johnson Foundation (RWJF) to provide ... disadvantaged backgrounds in an accelerated nursing degree program. ... Career Alternative RN Education, or CARE, Program, expanding ...
... HILL Nearly every child who receives an antipsychotic ... atypical drugs, such as olanzapine and risperidone. However, there ... effective than the older, first-generation medications., ,Now a study ... School of Medicine suggests that molindone, a first-generation drug, ...
Cached Medicine News:Health News:Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively 2Health News:Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively 3Health News:Web Site Helps Cancer Patients With Fertility Preservation 2Health News:CLEAN & CLEAR(R) Is Inviting Teens to 'Erase Their Worst Yearbook Picture' With The NEW CLEAN & CLEAR(R) Advantage(R) Blackhead Eraser(TM) Exfoliating Cleanser 2Health News:Proposed Assisted Living Regulations Would Allow Facilities to Rent Inaccessible Rooms to Persons Who Use Wheelchairs or Walkers 2Health News:Proposed Assisted Living Regulations Would Allow Facilities to Rent Inaccessible Rooms to Persons Who Use Wheelchairs or Walkers 3Health News:LSUHSC awarded grant to address nursing shortage 2Health News:First generation antipsychotic drugs as effective as newer ones in some children 2Health News:First generation antipsychotic drugs as effective as newer ones in some children 3
... The Integrity ADx pacemaker ... world's smallest dual-chamber pacemaker, ... pacemaker technology, including the ... the first U.S. commercially ...
... The Affinity pacemaker ... today's smallest, truly automatic ... effective combination of advanced ... Affinity DR pacemaker incorporates ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
... The first-ever completely automatic ... that make it sophisticated yet ... a wide range of diagnostic ... without clinician intervention. This allows ...
Medicine Products: